At Tithon, we are committed to providing resources to pet and horse owners and to the veterinarian medical community at large with the goal of assisting pets and horses suffering from degenerative medical conditions.
Tithon’s advanced technologies, products, methods, processes and procedures are based on research undertaken by pioneers in the cell therapy research field, assisted by university researchers and practicing veterinarian medical specialists. We are committed to developing revolutionary treatment options for those pets and horses suffering from degenerative medical conditions, options that are both safe and effective.
To this end, we are introducing to a limited number of veterinarian physicians an advanced proprietary method and process for obtaining from your pet’s or horse’s peripheral blood, therapeutic quantities of a recently discovered pluripotent stem cells, which participating veterinarians report have been successful in addressing a number of degenerative medical conditions.
Further, to this end, we are also completing development and will soon introduce a newly developed Antigen-Specific Immunotherapy product line commencing with K9 DeSense-D, an Isopathic Sarcode developed to address Canine Type-1 Diabetes, which will be followed by additional Antigen-Specific Immunotherapy based products addressing other canine and feline autoimmune conditions.
We are focused on developing new and improved solutions for improving the life of companion animals and horses through bioscience, focusing on stem cells and blood fractions including, platelet rich plasma, shown to address various common degenerative conditions along with our newly developed technology addressing certain autoimmune conditions.
We are the successor to years of scientific research conducted by pioneers in the field of Adipose derived stem cells, and we are the benefactor of continuing efforts through research conducted both in proprietary laboratory facilities, and affiliate private and university research centres, all dedicated to the cause of further understanding and unlocking the great potential of regenerative medicine.
We have been granted world-wide licenses to commercialize all animal applications of technologies and products developed by pioneers in the field of stem cell and other biotechnology fields, including:
- The collection, processing and photo-activation methods for both Adipose Stem Cells and Platelet Rich Plasma;
- The collection and processing method of a novel newly discovered pluripotent stem cell derived from peripheral blood, which early clinical testing indicates holds promise in treating a number of degenerative conditions; and
- A unique proprietary Antigen-Specific Immunotherapy Technology based on the use of isopathic sarcodes to address certain autoimmune conditions in animals.